Media
News & Events
Ferrer acquires worldwide rights to ASN90, exclusively to treat PSP
Ferrer acquires worldwide rights to ASN90, an O-GlcNAcase inhibitor from Asceneuron, exclusively to treat Progressive Supranuclear Palsy (PSP)
Asceneuron Awarded Grant from The Michael J. Fox Foundation
Asceneuron Awarded Second Grant from The Michael J. Fox Foundation for Accelerated Research into Novel Parkinson’s Disease Therapies
Asceneuron Publishes Preclinical Efficacy Data on ASN90
Asceneuron Publishes Pioneering Preclinical Efficacy Data on its Novel Clinical Molecule ASN90 in Both Alzheimer’s and Parkinson’s Disease Models
Asceneuron to Provide Update on O-GlcNAcase Pipeline
Asceneuron to Provide Update on O-GlcNAcase Pipeline at Upcoming Conferences
Asceneuron CEO Dirk Beher to speak at AAIC 2021
Asceneuron CEO Dirk Beher to speak at Alzheimer’s Association International Conference
Asceneuron Appoints Catherine Moukheibir to its Board of Directors
Asceneuron Appoints Prominent Healthcare Leader Catherine Moukheibir to its Board of Directors
Asceneuron appoints Dr Eric Yuen to the Board of Directors
Asceneuron appoints experienced CNS clinician Dr Eric Yuen to the Board of Directors
Asceneuron appoints Peter Van Vlasselaer as Chairman
Asceneuron appoints Peter Van Vlasselaer as Chairman
Asceneuron appoints Dr. Thomas C. Wessel as Chief Medical Officer
Asceneuron appoints Dr. Thomas C. Wessel as Chief Medical Officer
Asceneuron initiates neuroimaging trial for ASN120290
Asceneuron initiates neuroimaging trial for tau modifier ASN120290